Alternating hemiplegia of childhood

Last updated
Alternating hemiplegia of childhood
Other namesAHC
Specialty Neurology   OOjs UI icon edit-ltr-progressive.svg

Alternating hemiplegia of childhood (AHC) is an ultra-rare neurological disorder named for the transient episodes, often referred to as "attacks", of hemiplegia (weakness or paralysis) that those with the condition experience. It typically presents before the age of 18 months. These hemiplegic attacks can cause anything from mild weakness to complete paralysis on one or both sides of the body, and they can vary greatly in duration. Attacks may also alternate from one side of the body to the other, or alternate between affecting one or both sides during a single attack. Besides hemiplegia, symptoms of the disorder include an extremely broad range of neurological and developmental impairments which are not well understood. Normally, hemiplegia and other associated symptoms cease completely with sleep, but they may recur upon waking. [1]

Contents

Most frequently AHC is caused by a spontaneous mutation in the ATP1A3 gene. [2] [3] [4] It is an extremely rare disorder – approximately one in one million people have AHC. It was only recently discovered, having first been characterized in 1971. [4] [5]

Signs and symptoms

AHC patients exhibit a wide range of symptoms in addition to hemiplegic attacks. [1] These can be further characterized as paroxysmal and non-paroxysmal symptoms. Paroxysmal symptoms are generally associated with hemiplegic attacks and may occur suddenly with hemiplegia or on their own. Paroxysmal symptoms may last for variable amounts of time. Non-paroxysmal symptoms tend to be side effects of AHC which are present at all times, not just during episodes or attacks. Epilepsy, which is also considered a paroxysmal symptom, plays an important role in the progression and diagnosis of AHC.[ citation needed ]

Hemiplegic attacks

Chronologically, hemiplegic attacks are not always the first symptom of AHC, but they are the most prominent symptom, as well as the symptom for which the disorder is named. Hemiplegic attacks may affect one or both sides of the body, and attacks which affect both sides of the body may be referred to as either bilateral or quadriplegic attacks. One of the unique characteristics of AHC is that hemiplegic attacks, as well as other symptoms which may co-occur with hemiplegia, cease immediately upon sleep. During strong attacks, the symptoms may reoccur upon waking. [4] [6] Hemiplegic attacks can occur suddenly or gradually, and the severity of an attack can vary over its duration. [6] The attacks may alternate from one side of the body to another, though this is rare. [7] The length of attacks may also vary from minutes to weeks, [4] though the length of attacks varies more greatly between people than between attacks for one person. [6] Both bilateral and hemiplegic attacks are associated with pseudobulbar features such as dysphagia, dysarthria, and respiratory difficulty. [4] [6] [7] Paralysis is also often accompanied by changes in skin color and temperature, sweating, restlessness, tremor, screaming, and the appearance of pain. [6] Hemiplegic attacks happen irregularly and can occur with speech, eating, and swallowing impairment. Patients with AHC are frequently underweight due to these side effects. [7] The average age of onset for hemiplegic episodes has been found to be 6–7 months of age. [4] This early onset gives the name of this disorder the slightly misleading ending "of childhood". AHC is not exclusively limited to childhood – attacks in some cases become milder after the first ten years of life, but they never completely disappear. [7]

Paroxysmal symptoms

AHC patients have exhibited various paroxysmal symptoms which manifest to different degrees in each person. [6] Paroxysmal symptoms include tonic, tonic–clonic, or myoclonic limb movements, [8] dystonic posturing, choreoathetosis, ocular nystagmus, and various other ocular motor abnormalities. [1] [6] Almost half of all people have dystonic symptoms prior to experiencing hemiplegia. [4] These symptoms generally begin before 8 months of age. [8] Ocular motor abnormalities occur early, and these are the most frequent early symptoms of AHC, particularly nystagmus. [4] [6] Almost 1/3 of people with this disorder had episodic ocular motor features within 1–2 days of birth. Many also experienced hemiplegia and dystonia before 3 months of age. [4] A final symptom that may be considered paroxysmal is a temporary change in behavior - some patients will become unreasonable, demanding, and aggressive either before or after an attack. [9]

Not all patients have all of these symptoms, and it is not known whether they are caused by AHC. [1] Symptoms usually manifest in the first 3 months of the child's life, with an average onset of 2.5 months. Frequently, some of these symptoms will manifest in the neonatal period. These paroxysmal symptoms are often used to help diagnose AHC, since there is no simple test for it.[ citation needed ]

In some cases, EEGs taken during these paroxysmal events were characterized by a generalized background slowing. [4] [8] Overall however, EEG during episodes and other investigative methods such as brain MRI, TACs, angiographic MRIs and CFS have normal results. [10]

Non-paroxysmal symptoms

In the long term, many paroxysmal symptoms occur along with AHC, and while these symptoms vary in strength depending on the person, they are consistent features of AHC. [11] It is thought that some of these symptoms are brought on or worsened by hemiplegic attacks, though it is not known for certain. Patients experience persistent motor, movement (ataxia), and cognitive deficits. [4] [6] [7] These deficits become more apparent over time and include developmental delays, social problems, and retardation. [1] It is rare for someone with AHC not to have cognitive deficits, but a study in Japan did find two patients who met all of the diagnostic criteria for AHC but who were not mentally impaired. [12] It is not known whether AHC is a progressive disease, but severe attacks are suspected to cause damage which results in permanent loss of function. [7] 100% of children studied in the USA have had some form of mental impairment, which is usually described as mild to moderate, [4] but varies greatly among individuals.

Epilepsy

At least 50% of people with AHC also have epilepsy, [4] and AHC is often misdiagnosed as epilepsy because of this. [7] These epileptic events are distinguished from other episodes by an alteration of consciousness, as well as frequent tonic or tonic–clonic activity. Epileptic episodes are generally rare, though they do increase with age. Due to the rarity of epileptic episodes, there are few EEG confirmations of them.[ citation needed ]

Cause

Recent research suggests that AHC is caused by a de novo (spontaneous) genetic mutation in the ATP1A3 gene [13] [14] [2] on chromosome 19 (locus 19q13.31) which encodes enzyme ATP1A3. A small number of cases seem to be caused by a mutation in the ATP1A2 gene. [14] Where the mutation is inherited, it has the autosomal dominant pattern of inheritance. [14]

Previously AHC was thought to be a form of complicated migraine because of strong family histories of migraine reported in AHC cases. [4] AHC has also been considered to be a movement disorder or a form of epilepsy. Suggested causes have included channelopathy, mitochondrial dysfunction, and cerebrovascular dysfunction. [9] The disorder most closely related to AHC is familial hemiplegic migraine which is caused by a mutation in a gene for calcium channel receptors. It was thus thought that AHC may be caused by a similar channelopathy. [12]

Diagnosis

As of 1993 only approximately 30 people with AHC had been described in scientific literature. [6] Due to the rarity and complexity of AHC, it is not unusual for the initial diagnosis to be incorrect, or for diagnosis to be delayed for several months after the initial symptoms become apparent. [7] The average age of diagnosis is just over 36 months. [4] Diagnosis of AHC is not only difficult because of its rarity, but because there is no diagnostic test, making this a diagnosis of exclusion. There are several generally accepted criteria which define this disorder, however other conditions with a similar presentation, such as HSV encephalitis, must first be ruled out. Due to these diagnostic difficulties, it is possible that the commonness of the disease is underestimated.[ citation needed ]

The following descriptions are commonly used in the diagnosis of AHC. The initial four criteria for classifying AHC were that it begins before 18 months of age, includes attacks of both hemiplegia on either side of the body, as well as other autonomic problems such as involuntary eye movement (episodic monocular nystagmus), improper eye alignment, choreoathetosis, and sustained muscle contractions (dystonia). [4] [6] Finally, those with the condition often develop intellectual disabilities, delayed development, and other neurological conditions. [7] [9] These diagnostic criteria were updated in 1993 to include the fact that all of these symptoms dissipate immediately upon sleeping. Diagnostic criteria were also expanded to include episodes of bilateral hemiplegia which shifted from one side of the body to the other. [9]

Recent criteria have been proposed for screening for AHC early, in order to improve the diagnostic timeline. These screening criteria include focal or unilateral paroxysmal dystonia in the first 6 months of life, as well as the possibility of flaccid hemiplegia either with or separate from these symptoms. Paroxysmal ocular movements should also be considered, and these should include both binocular and monocular symptoms which show in the first 3 months of life. [4]

Treatments

Overall outcomes for AHC are generally poor, which is contributed to by AHC's various diagnostic and management challenges. In the long term, AHC is debilitating due to both the hemiplegic attacks and permanent damage associated with AHC. This damage can include cognitive impairment, behavioral and psychiatric disorders, and various motor impairments. [7] There is, however, not yet any conclusive evidence that AHC is fatal or that it shortens life expectancy, but the relatively recent discovery of the disorder makes large data for this type of information unavailable. Treatment for AHC has not been extremely successful, and there is no cure. [1] There are several drugs available for treatment, as well as management strategies for preventing and dealing with hemiplegic attacks.[ citation needed ]

Management strategies

Hemiplegic attacks can be brought on by particular triggers, and management of AHC often centers around avoiding common or known triggers. While triggers vary greatly from person to person, there are also some common ones which are prevalent in many patients. Common triggers include temperature changes, water exposure, bright lights, certain foods, emotional stress, and physical activity. While avoiding triggers may help, it cannot prevent all hemiplegic episodes because many occur without being triggered. Because attacks and other associated symptoms end with sleep, various sedatives can be used to help patients sleep. [4] [7]

Flunarizine

The most common drug used to treat AHC is flunarizine. Flunarizine functions by acting as a calcium channel blocker. Other drugs, in order of frequency of use are benzodiazepines, carbamazapine, barbiturates, and valproic acid. Flunarizine is prescribed for the purpose of reducing the severity of AHC attacks and the number of episodes, though it rarely stops attacks altogether. [4] Minimizing the attacks may help reduce damage to the body from hemiplegic attacks and improve long-term outcomes as far as mental and physical disabilities are concerned. [1] [12]

Experts differ in their confidence in flunarizine's effectiveness. [6] [12] Some studies have found it to be very effective in reducing the duration, severity, and frequency of hemiplegic attacks. [12] It is generally considered the best treatment available, but this drug is thought by some to be of little benefit to AHC patients. Many affected people experience adverse effects without seeing any improvement. [6] Flunarizine also causes problems because it is difficult for patients to obtain, as it is not readily available in the United States.[ citation needed ]

Sodium oxybate

In 2009 through 2011 clinical research at the University of Utah investigated whether sodium oxybate, also known as gamma-hydroxybutyric acid is an effective treatment for AHC. [15] Thus far, only a small number of patients have been sampled, and no conclusive results are yet available. While some success has been had thus far with the drug, AHC patients have been known to respond well initially to other drugs, but then the effectiveness will decline over time. Currently, sodium oxybate is used as a narcolepsy-cataplexy treatment, though in the past it has been used controversially in nutritional supplements. This drug was chosen to test because of a possible link between the causes of narcolepsy-cataplexy and AHC.[ citation needed ]

Related Research Articles

A headache is often present in patients with epilepsy. If the headache occurs in the vicinity of a seizure, it is defined as peri-ictal headache, which can occur either before (pre-ictal) or after (post-ictal) the seizure, to which the term ictal refers. An ictal headache itself may or may not be an epileptic manifestation. In the first case it is defined as ictal epileptic headache or simply epileptic headache. It is a real painful seizure, that can remain isolated or be followed by other manifestations of the seizure. On the other hand, the ictal non-epileptic headache is a headache that occurs during a seizure but it is not due to an epileptic mechanism. When the headache does not occur in the vicinity of a seizure it is defined as inter-ictal headache. In this case it is a disorder autonomous from epilepsy, that is a comorbidity.

Landau–Kleffner syndrome (LKS)—also called is a rare disease with acquired aphasia, acquired epileptic aphasia or aphasia with convulsive disorder—is a rare childhood neurological syndrome.

Psychogenic non-epileptic seizures (PNES), also referred to as pseudoseizures, non-epileptic attack disorder (NEAD), functional seizures, or dissociative seizures, are episodes resembling an epileptic seizure but without the characteristic electrical discharges associated with epilepsy. PNES fall under the category of disorders known as functional neurological disorders (FND), also known as conversion disorders, and are typically treated by psychologists or psychiatrists. PNES has previously been called stress seizures and hysterical seizures, but these terms have fallen out of favor.

<span class="mw-page-title-main">Monoplegia</span> Paralysis of a single limb

Monoplegia is paralysis of a single limb, usually an arm. Common symptoms associated with monoplegic patients are weakness, numbness, and pain in the affected limb. Monoplegia is a type of paralysis that falls under hemiplegia. While hemiplegia is paralysis of half of the body, monoplegia is localized to a single limb or to a specific region of the body. Monoplegia of the upper limb is sometimes referred to as brachial monoplegia, and that of the lower limb is called crural monoplegia. Monoplegia in the lower extremities is not as common of an occurrence as in the upper extremities. Monoparesis is a similar, but less severe, condition because one limb is very weak, not paralyzed. For more information, see paresis.

<span class="mw-page-title-main">Transient global amnesia</span> Temporary disruption of short-term memory

Transient global amnesia (TGA) is a neurological disorder whose key defining characteristic is a temporary but almost total disruption of short-term memory with a range of problems accessing older memories. A person in a state of TGA exhibits no other signs of impaired cognitive functioning but recalls only the last few moments of consciousness, as well as possibly a few deeply encoded facts of the individual's past, such as their childhood, family, or home perhaps.

Familial hemiplegic migraine (FHM) is an autosomal dominant type of hemiplegic migraine that typically includes weakness of half the body which can last for hours, days, or weeks. It can be accompanied by other symptoms, such as ataxia, coma, and paralysis. Migraine attacks may be provoked by minor head trauma. Some cases of minor head trauma in patients with hemiplegic migraine can develop into delayed cerebral edema, a life-threatening medical emergency. Clinical overlap occurs in some FHM patients with episodic ataxia type 2 and spinocerebellar ataxia type 6, benign familial infantile epilepsy, and alternating hemiplegia of childhood.

<span class="mw-page-title-main">Flunarizine</span> Calcium channel blocker medication

Flunarizine, sold under the brand name Sibelium among others, is a drug classified as a calcium antagonist which is used for various indications. It is not available by prescription in the United States or Japan. The drug was discovered at Janssen Pharmaceutica (R14950) in 1968.

<span class="mw-page-title-main">Hemiplegic migraine</span> Medical condition

Hemiplegic migraine is a type of migraine headache characterized by motor weakness affecting only one side of the body, accompanied by aura. There is often an impairment in vision, speech, or sensation. It can run in the family, called familial hemiplegic migraine, or in a single individual, called sporadic hemiplegic migraine. The symptoms can be similar to a stroke, and may be precipitated by minor head trauma. People with FHM are advised to avoid activities that may trigger their attacks.

Episodic ataxia (EA) is an autosomal dominant disorder characterized by sporadic bouts of ataxia with or without myokymia. There are seven types recognized but the majority are due to two recognized entities. Ataxia can be provoked by psychological stress or startle, or heavy exertion, including exercise. Symptoms can first appear in infancy. There are at least six loci for EA, of which 4 are known genes. Some patients with EA also have migraine or progressive cerebellar degenerative disorders, symptomatic of either familial hemiplegic migraine or spinocerebellar ataxia. Some patients respond to acetazolamide though others do not.

<span class="mw-page-title-main">GLUT1 deficiency</span> Medical condition


GLUT1 deficiency syndrome, also known as GLUT1-DS, De Vivo disease or Glucose transporter type 1 deficiency syndrome, is an autosomal dominant genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier. Glucose Transporter Type 1 Deficiency Syndrome has an estimated birth incidence of 1 in 90,000 to 1 in 24,300. This birth incidence translates to an estimated prevalence of 3,000 to 7,000 in the U.S.

Paroxysmal extreme pain disorder originally named familial rectal pain syndrome, is a rare disorder whose most notable features are pain in the mandibular, ocular and rectal areas as well as flushing. PEPD often first manifests at the beginning of life, perhaps even in utero, with symptoms persisting throughout life. PEPD symptoms are reminiscent of primary erythromelalgia, as both result in flushing and episodic pain, though pain is typically present in the extremities for primary erythromelalgia. Both of these disorders have recently been shown to be allelic, both caused by mutations in the voltage-gated sodium channel NaV1.7 encoded by the gene SCN9A. A different mutation in the SCN9A ion channel causes congenital insensitivity to pain.

The paroxysmal dyskinesias (PD) are a group of movement disorders characterized by attacks of hyperkinesia with intact consciousness. Paroxysmal dyskinesia is a rare disorder, however the number of individuals it affects remains unclear. There are three different subtypes of PD that include paroxysmal kinesigenic dyskinesia (PKD), paroxysmal nonkinesigenic dyskinesia (PNKD), and paroxysmal exercise-induced dyskinesia (PED). Other neurological diseases have similar symptoms to PD, such as epilepsy and Parkinson's. The different subtypes make accurate and quick diagnosis of PD challenging. Thus, PD is often under reported and misdiagnosed, making it difficult to accurately study its prevalence in human populations. Onset of PD is usually in late childhood to early adolescence. New drug regimens help treat symptoms of PD, but no cure for the disorder is known.

<span class="mw-page-title-main">Paroxysmal kinesigenic choreoathetosis</span> Medical condition

Paroxysmal kinesigenic choreoathetosis (PKC) also called paroxysmal kinesigenic dyskinesia (PKD) is a rare hyperkinetic movement disorder characterized by attacks of involuntary movements, which are triggered by sudden voluntary movements. The number of attacks can increase during puberty and decrease in a person's 20s to 30s. Involuntary movements can take many forms such as ballism, chorea or dystonia and usually only affect one side of the body or one limb in particular.

<span class="mw-page-title-main">Paroxysmal exercise-induced dystonia</span> Medical condition

Paroxysmal exercise-induced dystonia or PED is a rare neurological disorder characterized by sudden, transient, involuntary movements, often including repetitive twisting motions and painful posturing triggered by exercise or other physical exertion. PED is in the class of paroxysmal dyskinesia which are a group of rare movement disorders characterized by attacks of hyperkinesia with intact consciousness. The term paroxysmal indicates that the episodes are sudden and short lived and usually unpredicted, and return to normal is rapid. The number of reported cases of people with PED is very small leading to difficulty in studying and classifying this disease and most studies are limited to a very small number of test subjects.

Vestibular migraine (VM) is vertigo with migraine, either as a symptom of migraine or as a related neurological disorder.

Forced Normalization (FN) is a psychiatric phenomenon in which a long term episodic epilepsy or migraine disorder is treated, and, although the electroencephalogram (EEG) appears to have stabilized, acute behavioral, mood, and psychological disturbances begin to manifest. If, or when, treatment for the disorder is halted, the disturbances go away, but the episodic spikes on the EEG reappear. H. Landolt coined the term 'Forced Normalization' in 1953 in response to a change he witnessed in epileptic EEGs, which monitor electrical activity in the brain. These changes were followed by abrupt behavioral changes in the patient. Landolt concluded that forced normalization is "the phenomenon characterized by the fact that, with the occurrence of psychotic states, the electroencephalography becomes more normal or entirely normal, as compared with previous and subsequent EEG findings." Forced normalization, as described by Landolt, was therefore an electrophysiological phenomenon with the electroencephalograph at its helm.

Epilepsy-intellectual disability in females also known as PCDH19 gene-related epilepsy or epileptic encephalopathy, early infantile, 9 (EIEE9), is a rare type of epilepsy that affects predominately females and is characterized by clusters of brief seizures, which start in infancy or early childhood, and is occasionally accompanied by varying degrees of cognitive impairment. The striking pattern of onset seizures at a young age, genetic testing and laboratory results, potential developmental delays or developmental regression and associated disorders, eases diagnosis.

Abdominal migraine(AM) is a functional disorder that usually manifests in childhood and adolescence, without a clear pathologic mechanism or biochemical irregularity. Children frequently experience sporadic episodes of excruciating central abdominal pain accompanied by migrainous symptoms like nausea, vomiting, severe headaches, and general pallor. Abdominal migraine can be diagnosed based on clinical criteria and the exclusion of other disorders.

Alternating hemiplegia is a form of hemiplegia that has an ipsilateral cranial nerve palsies and contralateral hemiplegia or hemiparesis of extremities of the body. The disorder is characterized by recurrent episodes of paralysis on one side of the body. There are multiple forms of alternating hemiplegia, Weber's syndrome, middle alternating hemiplegia, and inferior alternating hemiplegia. This type of syndrome can result from a unilateral lesion in the brainstem affecting both upper motor neurons and lower motor neurons. The muscles that would receive signals from these damaged upper motor neurons result in spastic paralysis. With a lesion in the brainstem, this affects the majority of limb and trunk muscles on the contralateral side due to the upper motor neurons decussation after the brainstem. The cranial nerves and cranial nerve nuclei are also located in the brainstem making them susceptible to damage from a brainstem lesion. Cranial nerves III (Oculomotor), VI (Abducens), and XII (Hypoglossal) are most often associated with this syndrome given their close proximity with the pyramidal tract, the location which upper motor neurons are in on their way to the spinal cord. Damages to these structures produce the ipsilateral presentation of paralysis or palsy due to the lack of cranial nerve decussation before innervating their target muscles. The paralysis may be brief or it may last for several days, many times the episodes will resolve after sleep. Some common symptoms of alternating hemiplegia are mental impairment, gait and balance difficulties, excessive sweating and changes in body temperature.

<span class="mw-page-title-main">Recurrent painful ophthalmoplegic neuropathy</span> Medical condition

Recurrent painful ophthalmoplegic neuropathy (RPON), previously known as ophthalmoplegic migraine (OM), is a rare neurological disorder that is characterized by repeated headache attacks and reversible ipsilateral paresis of one or more ocular cranial nerves (CN). Oculomotor nerve (CNIII) is by far the most common cranial nerve involves in RPON, while abducens nerve (CNVI) and trochlear nerve (CNIV) involvements are also reported. Globally, RPON was estimated to have an annual incidence rate of 0.7 per million as of 1990, no further epidemiological studies have been conducted. It occurs more often in children and females.

References

  1. 1 2 3 4 5 6 7 Alternating Hemiplegia of Childhood Foundation. "What is AHC?". Archived from the original on 10 November 2010. Retrieved 2010-11-29.
  2. 1 2 Heinzen, Erin L; Swoboda, Kathryn J; Hitomi, Yuki; Gurrieri, Fiorella; Nicole, Sophie; et al. (September 2012). "De novo mutations in ATP1A3 cause alternating hemiplegia of childhood". Nature Genetics. 44 (9): 1030–1034. doi:10.1038/ng.2358. PMC   3442240 . PMID   22842232.
  3. ↑ Rosewich, Hendrik; Thiele, Holger; Ohlenbusch, Andreas; Maschke, Ulrike; Altmüller, Janine; Frommolt, Peter; Zirn, Birgit; Ebinger, Friedrich; Siemes, Hartmut; Nürnberg, Peter; Brockmann, Knut; Gärtner, Jutta (September 2012). "Heterozygous de-novo mutations in ATP1A3 in patients with alternating hemiplegia of childhood: a whole-exome sequencing gene-identification study". The Lancet Neurology. 11 (9): 764–773. doi: 10.1016/S1474-4422(12)70182-5 . PMID   22850527. S2CID   24720135.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Sweney, Matthew T.; Silver, Kenneth; Gerard-Blanluet, Marion; Pedespan, Jean-Michel; Renault, Francis; Arzimanoglou, Alexis; Schlesinger-Massart, Mylynda; Lewelt, Aga J.; Reyna, Sandra P.; Swoboda, Kathryn J. (March 2009). "Alternating Hemiplegia of Childhood: Early Characteristics and Evolution of a Neurodevelopmental Syndrome". Pediatrics. 123 (3): e534–e541. doi:10.1542/peds.2008-2027. PMID   19254988. S2CID   12239930.
  5. ↑ Verret, Simon; Steele, John C. (1 April 1971). "Alternating Hemiplegia in Childhood: A Report of Eight Patients with Complicated Migraine Beginning in Infancy". Pediatrics. 47 (4): 675–680. doi:10.1542/peds.47.4.675. PMID   5089756. S2CID   10993002.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 Silver K, Andermann F (January 1993). "Alternating hemiplegia of childhood: a study of 10 patients and results of flunarizine treatment". Neurology. 43 (1): 36–41. doi:10.1212/WNL.43.1_Part_1.36. PMID   8423908. S2CID   21357009.
  7. 1 2 3 4 5 6 7 8 9 10 11 Neville BG, Ninan M (October 2007). "The treatment and management of alternating hemiplegia of childhood". Dev Med Child Neurol. 49 (10): 777–80. doi: 10.1111/j.1469-8749.2007.00777.x . PMID   17880649.
  8. 1 2 3 Saito Y, Inui T, Sakakibara T, Sugai K, Sakuma H, Sasaki M (August 2010). "Evolution of hemiplegic attacks and epileptic seizures in alternating hemiplegia of childhood". Epilepsy Res. 90 (3): 248–58. doi:10.1016/j.eplepsyres.2010.05.013. PMID   20580529. S2CID   23466521.
  9. 1 2 3 4 Haffejee S, Santosh PJ (January 2009). "Treatment of alternating hemiplegia of childhood with aripiprazole". Dev Med Child Neurol. 51 (1): 74–7. doi: 10.1111/j.1469-8749.2008.03192.x . PMID   19087103. S2CID   23480526.
  10. ↑ Mulas Delgado, Fernando; Smeyers Durá, Patricia Mª; Barbero Aguirre, Pedro; Pitarch, Inma; Velasco, Rosa P. (2002). "Hemiplejia alternante del lactante" [Alternating hemiplegia in young babies]. Revista de Neurología (in Spanish). 34 (2): 157–162. doi:10.33588/rn.3402.2001278. PMID   11988911.
  11. ↑ Vigevano F, Andermann F, Aicardi J (1995). Alternating hemiplegia of childhood. New York: Raven Press. pp. 207–212. ISBN   978-0-7817-0163-1.
  12. 1 2 3 4 5 Sasaki M, Sakuragawa N, Osawa M (August 2001). "Long-term effect of flunarizine on patients with alternating hemiplegia of childhood in Japan". Brain Dev. 23 (5): 303–5. doi:10.1016/S0387-7604(01)00229-7. PMID   11504600. S2CID   20522508.
  13. ↑ Reference, Genetics Home. "Alternating hemiplegia of childhood". Genetics Home Reference. Retrieved 2019-03-21.
  14. 1 2 3 "Alternating hemiplegia of childhood | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 2019-03-21.
  15. ↑ Clinical trial number NCT00931164 for "Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO) (AHC-SO)" at ClinicalTrials.gov
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.